Intellia Therapeutics, a genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, has announced the move to its new laboratory facilities at 40 Erie Street, in Cambridge.

“The field of genome editing is rapidly evolving and our work to develop therapies for patients requires that we have the infrastructure necessary for R&D growth and prepare for preclinical studies and clinical trials,” said Nessan Bermingham, Ph.D., chief executive officer and founder, Intellia Therapeutics. “To reach our goals, we continue to recruit top talent and ensure our quality workforce has the appropriate facilities and tools necessary to translate CRISPR/Cas9 into life-transforming products.”

“This new facility allows Intellia to further advance our scientific programs and to continue to leverage our Massachusetts location alongside leading biotech research and academic institutions,” Dr. Bermingham added.

The new Intellia headquarters was specifically designed to accommodate the company’s growing R&D, operations teams and administrative staff. Additionally, Intellia will maintain operations at its current facility at 130 Brookline Street in Cambridge. The new facility will increase Intellia’s total laboratory and office space from the current 15,000 sq. ft. to more than 80,000 sq. ft. and will allow the company to double its team to more than 200 employees.

“Intellia Therapeutics’ new headquarters is a testament to the potential of the company and the promise their transformative gene therapy represents to patients and their families living with severe and life-threatening diseases,” said Governor Charlie Baker. “The innovations coming out of Massachusetts have a dramatic impact across the global life sciences sector, and we look forward to Intellia Therapeutics’ continued growth and contributions to this field.”

“We are thrilled to celebrate Intellia Therapeutics’ growth as a great example of the opportunity available to companies in the Massachusetts life sciences ecosystem,” said Travis McCready, president and CEO of the Massachusetts Life Sciences Center. “The genomics space is exciting, carrying enormous potential for saving lives and improving patient care. Companies like Intellia have provided a strong blueprint for success to other genomics startups in Massachusetts.”

“We are excited to celebrate with Intellia Therapeutics as they take this significant step to expand into new headquarters,” said Robert K. Coughlin, president and CEO of MassBio. “We are proud to have Intellia as part of the Massachusetts life sciences community and look forward to their successes as they advance the use of cutting-edge genome editing to develop treatments and cures for patients around the world.”